SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Islander who wrote (3473)3/16/2000 10:29:00 AM
From: Terry D.  Read Replies (1) of 3702
 
islander. more on Oncolym from todays filing.

On March 8, 1999, Techniclone entered into a license agreement with Schering A.G., a major multinational pharmaceutical company, with respect to the development, manufacture and marketing of its direct tumor targeting agent candidate, Oncolym(R). Under the agreement, Schering A.G. controls the clinical development program and funds 80% of the clinical trial costs. The current Phase II/III clinical trial has been stopped by Schering A.G. Schering A.G. has advised the Company that they currently anticipate starting a Phase I/II dosing trial for 18 patients under a new dosing regiment during the second calendar quarter of 2000.

The original trials required a 3 dosage regiment. Schering doesn't think it's possible to financially compete with technologies already in use and is going for a 1 dosage trial.

Terry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News